Inspire Announces Date for Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2006 Financial Results.DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to report fourth quarter and full year 2006 financial results on Tuesday, February 27, 2007 before the market opens. Inspire's President and CEO, Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host a conference call and live webcast on Tuesday, February 27, 2007 at 10:00 a.m. ET.
DATE: Tuesday, February 27, 2007
TIME: 10:00 a.m. ET
WEBCAST: Live call and replay accessible at www.inspirepharm.com
LIVE CALL: (877) 780-2276, ID # 8403684 (U.S./Canada)
(973) 582-2757, ID # 8403684 (International)
REPLAY: (877) 519-4471, ID # 8403684 (U.S./Canada)
(973) 341-3080, ID # 8403684 (International)
Replay available until March 13, 2007
About Inspire Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. The research and development programs of Inspire are driven by extensive scientific experience in the therapeutic areas of ophthalmology and respiratory/allergy, and supported by expertise in the field of P2 receptors. Inspire is currently developing drug candidates for dry eye dry eye n. , cystic fibrosis and allergic rhinitis. Inspire's U.S.
specialty sales force promotes Elestat([R]) (epinastine HCI ophthalmic
solution) 0.05% for allergic conjunctivitis Keratoconjunctivitis characterized by decreased tear flow and thickening and hardening of the cornea and conjunctiva. Also called dry-eye syndrome, keratoconjunctivitis sicca. acute contagious conjunctivitis , acute epidemic conjunctivitis pinkeye; a highly contagious form of conjunctivitis caused by Haemophilus aegyptius. acute hemorrhagic conjunctivitis a contagious form due to infection with enteroviruses. allergic conjunctivitis conjunctival inflammation, itching, tearing, and redness caused by allergens. and Restasis([R])
(cyclosporine ophthalmic emulsion) 0.05% for dry eye, ophthalmology
products developed by Allergan, Inc. Elestat and Restasis are trademarks
owned by Allergan. For more information, visit www.inspirepharm.com.Forward-Looking Statements The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion